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Abstract
Introduction: Monotherapy with protease-inhibitors (MPI) may be an alternative to cART for HIV treatment. We assessed the
impact of this strategy on immune activation, bacterial translocation and inflammation.
Methods: We performed a cross-sectional study comparing patients on successful MPI (n40) with patients on cART (n20).
Activation, senescence, exhaustion and differentiation stage in CD4 and CD8 T lymphocyte subsets, markers of monocyte
activation, microbial translocation, inflammation, coagulation and low-level viremia were assessed.
Results: CD4 or CD8 T lymphocyte subset parameters were not significantly different between both groups. Conversely,
as compared with triple cART, MPI patients showed a higher proportion of activated monocytes (CD14 CD16CD163 cells,
p0.031), soluble markers of monocyte activation (sCD14 p0.004, sCD163 p0.002), microbial translocation (lipopoly-
saccharide (LPS)-binding protein; LBP p0.07), inflammation (IL-6 p0.04) and low-level viremia (p0.035). In a multivariate
model, a higher level of CD14 CD16CD163 cells and sCD14, and presence of very low-level viremia were independently
associated with MPI. Monocyte activation was independently associated with markers of inflammation (IL-6, p0.006),
microbial translocation (LBP, p0.01) and low-level viremia (p0.01).
Conclusions: Patients on MPI showed a higher level of monocyte activation than patients on standard therapy. Microbial
translocation and low-level viremia were associated with the high level of monocyte activation observed in patients on MPI. The
long-term clinical consequences of these findings should be assessed.
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Introduction
The introduction of HIV antiretroviral treatment has comple-
tely changed the spectrum of the illness that has become,
in the past years, a chronic condition in developed countries.
Prompt diagnosis has also permitted to treat patients earlier
and the proportion of patients that are first diagnosed with
a low number of CD4 T lymphocytes or with an opportu-
nistic infection has sharply decreased. With stable patients
on treatment and living longer, the morbidity associated with
medication and cost of treatment has notably increased.
Strategies for simplifying treatment and lowering the cost
have started to be implemented [1]. Monotherapy with
ritonavir-boosted protease inhibitor has been proposed as
one of these alternatives.
Several clinical trials have assessed the virological effective-
ness of simplification of a successful standard protease inhibi-
tor containing regimen to a protease inhibitor monotherapy.
The MONET and the MONOI studies compared ritonavir-
boosted darunavir in monotherapy versus the standard triple
therapy treatment. Both demonstrated non-inferiority in
the per-protocol analysis [2,3]. In the same way, the OK study
showed similar rates of viral suppression between the boosted
lopinavir monotherapy and the triple therapy group [4].
On the contrary, lower rates of virological suppression
were seen in the MONARK study in naı¨ve patients who started
monotherapy with boosted lopinavir as compared with
standard triple therapy containing regimen [5]. Finally, in the
MOST study virologically suppressed patients for at least
six months with standard cART were randomized to switch to
protease inhibitor monotherapy or to continue with triple
therapy. This study was prematurely stopped due to high rates
of virologic failure [6].
Overall, monotherapy seems an effective strategy in
patients previously suppressed with no prior virologic failure.
However, more episodes of transient viremia elevation have
been reported in the monotherapy groups included in the
studies [3,7], although a higher incidence of PI mutations was
not observed [3].
Efficacy in the above-cited clinical trials was determined
by viral load (VL) suppression, but no other variables were
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taken into account. Concerns about the possibility of a
higher immune activation in patients on monotherapy, or the
possibility of lower penetration in the central nervous system
were raised. Few studies were performed in an attempt to
answer this question. A retrospective study of the samples in
the MONET trial showed no differences in high-sensitive
C-reactive protein (hs-CRP) or interleukin-6 (IL-6) between
patients in monotherapy or triple therapy [8]. Suppression in
CSF has also been studied in patients on boosted lopinavir
monotherapy versus triple therapy, with similar findings in
both groups [9]. However, some case reports in the litera-
ture describe patients on PI monotherapy and with sup-
pressed VL in plasma who showed detectable VL in CSF
[10,11]. Moreover, in the MONOI trial, two patients in the
monotherapy group that presented neurological symptoms
showed VL escape in the CSF when a lumbar puncture was
performed [3].
We hypothesized that patients on monotherapy could
have a higher level of immune activation than patients
on cART and, therefore, were at higher risk of suffering
long-term clinical consequences (i.e. non-AIDS events). Here,
we perform a study to compare the impact of successful
monotherapy, either with boosted darunavir or boosted
lopinavir, on immune activation, microbial translocation and
other inflammatory markers.
Patients and methods
Patients
Forty patients on antiretroviral treatment who had success-
fully simplified to monotherapy either with ritonavir-boosted
darunavir or ritonavir-boosted lopinavir (MPI group) were
recruited between September 2011 and September 2012 in
the outpatient HIV clinic in the Hospital Clinic, Barcelona.
Patients had to fulfil the following inclusion criteria: age over
18 years, antiretroviral treatment with monotherapy for at
least the previous 48 weeks and VL B37 copies/ml in the
blood tests performed in the previous 48 weeks. Patients
fulfilling the inclusion criteria and willing to participate signed
informed consent and an extraction of 60 ml of blood
was performed. Twenty patients on triple therapy with a
PI-containing regimen (ritonavir-boosted darunavir or lopinavir)
(cART group) were recruited as a comparison group. To parti-
cipate in the study, written informed consent was obtained
from all individuals, and the study protocol was evaluated
and approved by the Hospital Ethical Committee.
VL measurement
Plasma HIV-RNA was measured using Versant HIV-1 RNA v3.0
(Siemens, Barcelona, Spain), which has a lower limit of
detection and a lower limit of quantification of 37 copies/ml.
Patients with a plasma VL that was detectable but below
the limit of quantification (B37 copies/ml) were classified
as patients with very low-level viremia (VLLV), and those
patients with VL reported as not detected were classified as
undetectable [13].
Cell samples
All analyses were done in freshly isolated peripheral blood
mononuclear cells (PBMCs). EDTA-anticoagulated blood was
obtained by venipuncture; PBMCs were immediately isolated
by density gradient centrifugation using Ficoll-Hypaque
(Sigma Chemical Co., St. Louis, MO). We used a compre-
hensive approach of simultaneous measurement of differ-
ent immunological parameters [12] in CD4 and CD8 T
lymphocyte: activation (using CD38 and HLADR markers),
senescence (using CD28 and CD57 marker), exhaustion (using
PD-1 marker), co-receptor expression (CCR5, CXCR4), differ-
entiation stage (using CD45RA and CD45RO markers) and
monocyte activation (using CD14, CD16 and CD163 markers).
The stained cells were analyzed on a FACSCalibur (Becton
Dickinson, San Jose, CA) cytometer. Flow cytometry gating
strategy for monocytes is shown in Figure 1. Data were
analyzed using FlowJo Software (Tree Star).
Soluble markers of monocyte activation, microbial
translocation, inflammation and coagulation markers
Serum was initially frozen at a temperature of 808C. Soluble
markers of monocyte activation [soluble CD14 (sCD14) and
soluble CD163 (sCD163)], markers of host response to lipo-
polysaccharide (LPS) [LPS-binding protein (LBP), endotoxin-
core IgM antibody (EndoCAb)], inflammation [high-sensitive
C-reactive protein (hs-CRP), interleukin-6 (IL-6), tumour ne-
crosis factor-alpha (TNF-alpha)] and pro-coagulation (D-dimer)
were assessed.
Soluble CD14 was determined with Quantikine ELISA
(R&D systems; limit of detection 125 pg/ml; intra-assay
variability is 4.86.4%); and soluble CD163 was determined
by Macro163 ELISA (IQ products; limit of detection 0.23 ng/
ml; intra-assay variability 36%) according to manufacturer’s
instructions. Human LBP and endotoxin-core antibodies were
determined by ELISA (Hycult biotech; limit of detection
4.4 ng/ml and 0.05 MMU/ml, respectively). High-sensitive
CRP was determined by an immune turbidimetric method
(CardioPhase, Siemens Healthcare Diagnostics). A result
over 0.5 mg/dl was considered positive. IL-6 and TNF-
alpha were determined by ELISA (Diasource Immunoassays,
Figure 1. Identification and analysis of monocyte subpopulations.
(A) Gated monocytes were subdivided into monocyte subpopula-
tions on the basis of CD14 and CD16 staining characteristics.
Subpopulations are defined as CD14 CD16 (quadrant 1),
CD14 CD16 (quadrant 2), CD14 CD16 (quadrant 3),
and CD14-CD16 (quadrant 4). The percentage of cells for each
population is depicted in the outer most corner. (B) CD163
activation marker was measured according to the flow cytometry
gating strategy indicated above in CD14CD16 (Q3) and CD14
CD16 (Q1Q2).
Torres B et al. Journal of the International AIDS Society 2014, 17:19246
http://www.jiasociety.org/index.php/jias/article/view/19246 | http://dx.doi.org/10.7448/IAS.17.1.19246
2
Louvain-la-Neuve, Belgium). Results over 5 and 10 pg/ml,
respectively, were considered positive. D-dimer was used as
a pro-coagulation marker. It was measured with a turbidi-
metric method (Innovance, Siemens Diagnostics, Marburg,
Germany) in a BCS automated coagulation system XP
(Siemens Diagnostics). The sensitivity of the technique allows
for the detection of levels as low as 10 ng/ml. The normal
cut-off is 500 ng/ml.
Statistical analysis
Characteristics of the study population and the different
immunological parameters, microbial translocation and in-
flammatory markers were recorded as median [interquartile
range], and comparisons were made using t-test or the non-
parametric tests MannWhitney U-test. Correlations be-
tween quantitative parameters were explored using the
Spearman’s rho test. Logistic regression was used to analyze
the factors independently associated with the type of therapy
(MPI vs. cART). Multiple regression was used to analyze the
factors independently associated with monocyte activation.
All statistical analyses were performed using the SPSS
software version 20 (SPSS Inc., Chicago, IL, USA). All p-values
were two-tailed, and were considered significant when lower
than 0.05.
Results
Clinical characteristics
No differences in age or gender were observed between
the two groups (Table 1). Patients with HCV co-infection were
equally distributed between groups. Patients on monother-
apy had a longer time since HIV diagnosis and had been
on antiretroviral treatment longer. The accumulated time
on a PI-containing regimen was longer for the patients on
monotherapy but without reaching statistical significant
difference. The median time on ritonavir-boosted protease
inhibitor monotherapy was 37 months (IQR: 1351 months).
CD4 T lymphocyte count at start of antiretroviral treat-
ment was lower in the MPI group; however, the CD4 T
lymphocyte count at the time of inclusion in the study was
similar between the two groups with a median 500 cells/
mm3 in both groups. No differences in plasma VL at the start
of antiretroviral treatment were seen between groups.
All patients had VL B37 copies in the last control performed
before the inclusion in the study, but in the blood test
performed the day of inclusion, four patients had detectable
VL (two patients in the MPI group with values 50 and
52 copies/ml, and two in the cART group, with values of 156
and 39 copies/ml).
Comparison of immunological parameters between MPI
and cART groups
No differences were observed in markers of T lymphocyte
activation, senescence, exhaustion, co-receptor expression or
differentiation stages between both groups (see Table 2).
Conversely, as compared with cART, MPI patients showed
a higher proportion of activated monocytes (CD14CD16
CD163 cells 9.63% vs. 7.53%, p0.033; CD14 CD16
CD163 cells 55.17% vs. 33.57%, p0.031 (Figure 2A); and
CD14CD16 cells 26.85% vs. 19.79%, p0.029, MPI vs.
cART groups)
Comparison of soluble markers of monocyte activation,
markers of microbial translocation, inflammation, pro-
coagulation and VLLV between MPI and cART groups
Levels of soluble markers of monocyte activation were
higher in MPI vs. cART patients [sCD14: 2133 vs. 1714 ng/ml,
p0.004 (Figure 2B); sCD163: 369 vs. 215 ng/ml, p0.002
(Figure 2C)] (Table 3). LBP levels, but not EndoCab were also
higher in MPI patients [LBP: 8948 vs. 8237 ng/ml, p0.07
(Figure 2D)]. Regarding inflammatory markers, only IL-6 levels
were significantly higher in the MPI group as compared with
cART (IL-6: 34.5 vs. 8 pg/ml, p0.04). D-dimer levels were
similar between both groups. Given that patients on mono-
therapy had a significantly longer time of known HIV infection
Table 1. Clinical characteristics of patients
Characteristic MPI group (n40) IP-containing triple therapy (n20) P
Age 49 (4557) 44 (4052) 0.71
Sex (female). no,% 11 (27.5) 4 (20) 0.753
Time since HIV diagnosis (months) 184.3 (146.3223.5) 96.9 (64.9222.3) 0.048
Time on ART (months) 167.5 (102.7183.0) 67.2 (39.8156.3) 0.006
Time on a PI-containing regimen (months) 91.4 (48.2123.7) 49.8 (22.0123.1) 0.074
VL B37 copies. no, % 38 (95) 18 (90) 0.595
VL at start of treatment (Log) 5,14 (4,065,49) 4,60 (4,085,49) 0.71
CD4 cell count (cells/mm3) at inclusion 566 (390830) 568 (429706) 0.660
CD4 cell count (cells/mm3) at start of treatment 192 (65281) 299 (119381) 0.03
CD4 cell count Nadir 145 (48227) 243 (118319) 0.16
HCV co-infection. no, % 9 (22.5) 5 (25) 1
Type of PI on the past 12 months (ABT/DRV) 26/14 12/8 0.780
VLviral load; ABTlopinavir/ritonavir; DRVdarunavir/ritonavir; PIprotease inhibitor; HCVhepatitis C virus; ARTantiretroviral
treatment; MPIMonotherapy with ritonavir-boosted protease inhibitor. cART: triple therapy with a PI-containing regimen (ritonavir-
boosted darunavir or lopinavir).
Data are in median [IQR], unless otherwise indicated.
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and a lower CD4 T lymphocyte count before starting cART
and these variables couldmean a bias to compare both groups,
we repeated the analysis controlling both variables, excluding
those patients on monotherapy with longer follow-up (more
than 12 years, lower IQR of MPI group) and lower CD4
T lymphocyte count previous to treatment (below 200 cells/
mm3,median value ofMPI group).The differences inmonocyte
activation, microbial translocation and inflammatory markers
between both groups were confirmed (data not shown).
Finally, we analyzed the presence of VLLV, defined as viremia
below limit of detection (37 copies) but qualitatively detect-
able. Fifteen out of 38 (39%) patients in the monotherapy
Table 2. Lymphocyte and monocyte subpopulations
Cell subset category Subpopulations (%) PI Monotherapy (n40) IP-containing triple therapy (n20) p
Activation of CD4 and CD8 T cells CD4 DR38 2.23 (1.593.73) 2.62 (1.573.91) 0.5483
CD8 DR38 8.3 (5.212.62) 8.33 (6.0114.73) 0.8525
Senescence CD4 2857 1.73 (0.643.55) 2.63 (0.835.18) 0.3944
CD8 2857 28.09 (18.1939.97) 31.71 (26.8743.95) 0.2363
Exhaustion CD4 PD1 20.54 (14.0230.33) 18.65 (16.5827.56) 0.7212
CD8 PD1 22.72 (18.3831.35) 25.30 (21.2929.52) 0.4605
Co-receptors CD4 CCR5 25.22 (12.5938.26) 24.63 (15.1329.36) 0.7030
CD8 CCR5 14.66 (7.4226.77) 16.85 (6.5923.24) 0.8839
Differentiation stage CD4 RARO 31.27 (24.4148.34) 31.88 (21.1340.84) 0.9032
CD8 RARO 46.40 (36.0954.47) 45.60 (36.3854.45) 0.9677
CD4 RA-RO 57.51 (40.7769.30) 57.81 (35.9463.45) 0.5008
CD8 RA-RO 40.06 (28.4952.23) 39.69 (25.2947.85) 0.5647
Monocyte activation CD1416163 9.63 (3.6515.62) 7.53 (3.239.09) 0.033
CD1416163 55.17 (31.5871.76) 33.57 (20.0053.53) 0.031
CD1416163 13.51 (10.8121.71) 12.04 (9.8815.97) 0.1518
CD1416 26.85 (18.9941.06) 19.79 (14.9425.88) 0.029
Figure 2. Comparison of the levels of monocyte activation and markers of microbial translocation between patients on triple protease
inhibitor regimen vs. patients on protease inhibitor monotherapy.
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group presented positive signal under the limit detec-
tion versus two out of 18 (11%) in the triple therapy one
(p0.035).
A multivariate analysis was performed to assess the factors
independently associatedwith the typeof therapy (MPI vs. cART).
Variables with statistically significant differences in univariate
analysis were included in the model. A higher level of CD14
CD16 CD163 cells (p0.023) and sCD14 (p0.013), and
presence of VLLV (p0.027) were independently associated
with MPI. We repeated the multivariate model controlling for
CD4 T lymphocyte at the start of the antiretroviral treatment,
CD4 T lymphocyte at inclusion, nadir CD4 T lymphocyte and
time of HIV infection. The results showed that CD14 CD16
CD163 cells and sCD14, but not VLLV, remained independently
associated with MPI.
Correlations among monocyte activation levels, markers of
microbial translocation and inflammatory markers
Patients with higher levels of monocyte activation showed
the higher levels of microbial translocation and inflamma-
tory markers. The levels of CD14CD16CD163 cells were
correlated with sCD14 (rho0.29, p0.039), sCD163
(rho0.26, p0.047), hsPCR (rho0.29, p0.02); the levels
of CD14CD16 cells were correlated with IL-6 (rho0.70,
p0.003) and TNF-alpha (rho0.36, p0.006); and the
levels of sCD14 with LBP (rho0.54, pB0.0001), hsPCR
(rho0.29, p0.038) and TNF-alpha (rho0.41, p0.003).
Markers of monocyte activation were not correlated with
CD4 Tcell at start of antiretroviral treatment or nadir CD4
T lymphocyte.
In a multivariate analysis (using in the model as depen-
dent variable either CD14CD16CD163 cells or CD14
CD16 cells), monocyte activation was independently asso-
ciated with markers of inflammation (IL-6, p0.006) and
low-level viremia (p0.01). In addition, in a multivariate
model using as dependent variable sCD14, this soluble
marker of monocyte activation was independently associated
with the marker of microbial translocation LBP (p0.028)
and low-level viremia (p0.05).
In addition to sCD14, the marker of microbial transloca-
tion LBP was directly correlated with sCD163 (rho0.28,
p0.034) and inflammatory markers hs-PCR (rho0.45,
pB0.0001) and TNF-alpha (rho0.37, p0.004).
Finally, as compared with patients with undetectable
level of VL, patients with VLLV showed a higher percentage
of CD14CD16CD163 cells [median 13.65, IQR (4.02
22.17) vs. 7.65 (4.2113.31), p0.029] and higher levels of
LBP [median 9964 ng/ml, IQR(845213,213) vs. 8574 (7820
9548), p0.025] (Figure 3).
Discussion
The results of our study show a higher level of monocyte
activation in patients on successful monotherapy with a
boosted PI as compared with protease inhibitor standard
regimen. The level of monocyte activation was associated
with markers of host response to microbial transloca-
tion, inflammation and low-level viremia. These data might
suggest that microbial translocation and VLLV drive the high
level of monocyte activation observed in these patients
on protease inhibitor monotherapy.
The first objective of our study was to assess if the
simplification to a successful monotherapy had an impact
on activation of the immune system. Although no differ-
ences were observed in the percentage of CD4 and CD8
T lymphocytes subpopulations (measuring activation, senes-
cence, exhaustion and differentiation stage), patients on
monotherapy with a boosted PI showed a higher level of
monocyte activation as measured by the expression of CD16
and CD163 in CD14 cells, and the levels in plasma of soluble
CD14 and CD163. Recent studies describe higher percentage
of markers of monocyte activation in HIV viremic patients
and, also in HIV-treated patients who, despite effective
antiretroviral treatment, still express higher monocyte
activation than age matched uninfected patients [14,15].
Table 3. Markers of bacterial translocation, inflammation, pro-coagulation and very low-level viremia
PI Monotherapy (n40) IP-containing triple therapy (n20) p
Bacterial translocation
LBP (ng/ml) 8948 (811510,999) 8237 (71719693) 0.07
sCD14 (ng/ml) 2133.18 (1847.132387.14) 1714.36 (1460.531904.20) 0.004
EndoCAb (MMU/ml) 68 (4499) 74 (34105) 0.47
sCD163 (ng/ml) 368 (279.76530.90) 215.38 (147.18292.23) 0.002
Inflammation
hs-CRP (mg/dl) 0.2 (0.080.46) 0.18 (0.090.33) 0.72
IL-6 (pg/ml) 34.5 (18258) 8 (827.5) 0.04
TNFa (pg/ml) 5 (47) 4.5 (47) 0.27
Pro-coagulation
D-dimer (ng/ml) 201 (90320) 176 (111269) 0.23
Viremia
Detection of VLLV. n (%) 15/38 (39.4) 2/18 (11) 0.03
LBPLipopolysaccharide-binding protein; sCD14soluble CD14; EndoCAbendotoxin core IgM antibody; sCD163soluble CD163; hs-
CRPhigh sensitive C-reactive protein; IL-6interleukin-6; VLLVvery low-level viremia. Data are in median (IQR) unless otherwise indicated.
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The marker CD16 is known to be expressed in more mature
monocytes with a distinct pattern of cytokine production
and they are considered to be proinflammatory monocytes
[16]. CD163 is a monocyte/macrophage haemoglobin sca-
venger receptor involved in the anti-inflammatory response
of monocytes [17]. CD163 is predominantly expressed in
CD14 CD16 monocytes in the general population and
in those who are HIV positive [17,18]. Surface expression of
CD163 also accounts for activation and can be co-expressed
altogether with CD16 [19]. Both CD163 and CD14 are shed
upon monocyte activation and the soluble form can be
detected in plasma. The increase of all these markers of
monocyte activation has been associated with clinical end-
points. The frequency of inflammatory CD16 monocytes
is associated with risk of coronary artery progression [20].
Soluble CD14 was reported to be an independent predictor
of mortality in HIV [21] and has been related to the increase
in the yearly rate of carotid intima-media thickness [22],
whereas soluble CD163 has been associated with increased
risk of coronary artery inflammation and atherosclerosis and
with subclinical atherosclerosis [23]. In addition, a study
that assessed neurocognitive impairment in virologically
suppressed HIV patients found higher levels of soluble
CD163 in patients with a higher global deficit score, sug-
gesting persistent monocyte activation in neuropsychological
impaired patients [24]. All these data suggest that the long-
term consequences of elevated monocyte activation in
patients on PI monotherapy should be further assessed in
longitudinal studies.
The second objective of the study was to investigate the
factors associated with monocyte activation in this cohort.
We found that patients with higher monocyte activation
had a higher level of IL-6, LBP and low-level of viremia.
These data might suggest that microbial translocation and
VLLV drive the monocyte activation in patients on protease
inhibitor monotherapy. We found that IL-6 was significantly
higher in the monotherapy group. It has been reported
that increases in concentrations of interleukin-6 are strongly
associated with all-cause mortality [25]. If the higher level of
IL-6 would be associated with a worse long-term clinical
outcome in these patients deserves further investigation.
Early gut mucosal destruction in HIV infection results in
microbial translocation and higher microbial products in the
circulation that are supposed to be partially responsible of
HIV-associated immune activation that persists despite the
introduction of the antiretroviral treatment [26]. A recent
study has shown an increase in mucosal macrophages in HIV
naı¨ve patients due to enhanced trafficking of blood mono-
cytes in the gut but with lower phagocytic activity [27].
In addition, products of microbial translocation, such as LPS,
bind to LBP and cause monocyte activation via toll-like
receptor 4 [28]. Higher microbial translocation is then closely
related to monocyte activation and has been related to
disease progression [29], neurocognitive impairment [30],
subclinical atherosclerosis [22] and other pathogenic condi-
tions as non-Hodgkin lymphoma [31] in HIV patients. Our
data support these findings, since we observed not only
that microbial translocation was associated with monocyte
activation, but that both microbial translocation and mono-
cyte activation were associated with an increase of inflam-
matory markers (hsPCR, IL-6 and TNF-alpha).
Finally, we observed that a higher number of patients
included in the MPI group presented with VLLV. The impor-
tance of VLLV has been a recent issue of interest. Some studies
have related VLLV to a higher risk of virologic failure, and
have suggested that low-level viral replication is a cause of
VLLV [32,33]. In our study, when we compared patients
with VLLV with patients with undetectable VL, we observed
a higher percentage of activated monocytes (CD14CD16
CD163) and levels of LBP in the first group, suggesting
a relation between VLLV and monocyte activation. Tradition-
ally, monocytes were considered to be non-permissive for
HIV infection. However, replication competent virus can be
detected following activation of these cells [34]. A study
that characterized HIV-1 RNA in treated patients with low-
level viremia (B48 copies) and examined the sources of
residual plasma viremia compared to that expressed in CD4
T lymphocytes and in CD14 CD16 monocytes observed
that plasma sequences were more related to that sequenced
in activatedmonocytes, suggesting that residual viremia found
in cART-suppressed patients could have its origin from cells
from the myeloid lineage [35]. We could hypothesize that
monotherapy with a boosted PI regimen is less able to control
viral replication in reservoirs as monocyte subsets, leading
to higher monocyte activation, inflammation and microbial
translocation.
Figure 3. Comparison of the levels of monocyte activation and markers of microbial translocation between patients with undetectable viral
load and patients with very low-level of viremia.
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We are aware that our study has other limitations. First
of all, it is a transversal study and a low number of patients
are included. Second, regarding baseline characteristics, the
CD4 T lymphocyte count at the start of treatment was
lower in the MPI group, although no significant differences
were observed in VL, nadir of CD4 or CD4 T lymphocyte
count at the time of inclusion. In fact, it has been reported
that clinically important CD4 T lymphocyte count re-
sponses are likely to be better defined in terms of absolute
postcART CD4 T lymphocyte counts, rather than change
from baseline [36]. In addition, we have recently reported
that differences in CD4 T lymphocyte gain with different
cART regimen are not immunologically meaningful [37].
Moreover, we have repeated the analysis controlling by
time of known HIV infection and CD4 T lymphocyte
count previous to cART and the results were confirmed.
Finally, VLLV as defined by plasma VL that was detectable
but below the limit of quantification could not be a good
measurement of the reservoir or residual viremia. In fact,
other studies [38,39] did not find an increase of the level
of persistent viremia as measured by Roche Amplicor HIV-1
RNA assay with a quantification limit of three copies/ml or by
single-copy assay. Apart from the technique used for the
measurement, the main difference with our study is that in
these studies residual viremia was assessed during the first
48 weeks of simplification, while in our study the median
time on monotherapy was three years and all of the patients
were on monotherapy for at least the previous 48 weeks
before the inclusion and had a VL B37 copies/ml in all
the blood tests performed in the previous 48 weeks. We
know that the best option for assessing persistent viremia
was to measure residual viremia directly; regretfully, we did
not have enough sample availability to measure it by other
techniques.
In summary, the higher monocyte activation observed in
the monotherapy group raises concern about this strategy
and the possible association with a higher mortality and long-
term cardiovascular and neurocognitive deleterious effects.
Larger clinical trials should be performed in order to confirm
these results.
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